🚀 VC round data is live in beta, check it out!
Mabwell Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mabwell and similar public comparables like Sarepta Therapeutics, Definium Therapeutics, Nanjing King-Friend, AstraZeneca Pharma India and more.
Mabwell Overview
About Mabwell
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
Founded
2017
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Mabwell Financials
Mabwell reported last 12-month revenue of $116M.
In the same LTM period, Mabwell generated had net loss of ($125M).
Revenue (LTM)
Mabwell P&L
In the most recent fiscal year, Mabwell reported revenue of $97M and EBITDA of ($95M).
Mabwell expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $116M | XXX | $97M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $88M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 90% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($95M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (98%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (128%) | XXX | XXX | XXX |
| Net Profit | ($125M) | XXX | ($141M) | XXX | XXX | XXX |
| Net Margin | (108%) | XXX | (145%) | XXX | XXX | XXX |
| Net Debt | — | — | $141M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mabwell Stock Performance
Mabwell has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Mabwell's stock price is $5.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-0.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMabwell Valuation Multiples
Mabwell trades at 21.3x EV/Revenue multiple, and (26.1x) EV/EBITDA.
EV / Revenue (LTM)
Mabwell Financial Valuation Multiples
As of April 19, 2026, Mabwell has market cap of $2B and EV of $2B.
Equity research analysts estimate Mabwell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mabwell has a P/E ratio of (18.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 21.3x | XXX | 25.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (26.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (19.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 28.2x | XXX | XXX | XXX |
| P/E | (18.1x) | XXX | (16.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (37.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mabwell Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mabwell Margins & Growth Rates
Mabwell's revenue in the last 12 month grew by 52%.
Mabwell Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 52% | XXX | 68% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (98%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (23%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 147% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 219% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mabwell Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mabwell | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarepta Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Definium Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanjing King-Friend | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca Pharma India | XXX | XXX | XXX | XXX | XXX | XXX |
| BioKangtai | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mabwell M&A Activity
Mabwell acquired XXX companies to date.
Last acquisition by Mabwell was on XXXXXXXX, XXXXX. Mabwell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mabwell
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMabwell Investment Activity
Mabwell invested in XXX companies to date.
Mabwell made its latest investment on XXXXXXXX, XXXXX. Mabwell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mabwell
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mabwell
| When was Mabwell founded? | Mabwell was founded in 2017. |
| Where is Mabwell headquartered? | Mabwell is headquartered in China. |
| Is Mabwell publicly listed? | Yes, Mabwell is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Mabwell? | Mabwell trades under 688062 ticker. |
| When did Mabwell go public? | Mabwell went public in 2022. |
| Who are competitors of Mabwell? | Mabwell main competitors are Sarepta Therapeutics, Definium Therapeutics, Nanjing King-Friend, AstraZeneca Pharma India. |
| What is the current market cap of Mabwell? | Mabwell's current market cap is $2B. |
| What is the current revenue of Mabwell? | Mabwell's last 12 months revenue is $116M. |
| What is the current revenue growth of Mabwell? | Mabwell revenue growth (NTM/LTM) is 52%. |
| What is the current EV/Revenue multiple of Mabwell? | Current revenue multiple of Mabwell is 21.3x. |
| Is Mabwell profitable? | No, Mabwell is not profitable. |
| What is the current net income of Mabwell? | Mabwell's last 12 months net income is ($125M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.